Funding announcement
Curlew Bio Joins MTM's Brisbane Pod
Molecule to Medicine announces Curlew Bio as the second venture in its Brisbane Pod, with Uniquest Expansion Fund backing, to develop immunological therapies for inflammatory disease.
Investor
Molecule to Medicine
Hawthorn East, VIC
Disclosed deals
Every published round Molecule to Medicine took part in, and every parcel of existing shares it bought off another holder. Deals we hold but haven't published yet are not counted, and a place in one of its own programs is under Cohorts.
Cohort members
Everyone Molecule to Medicine has named to a program in published coverage. A place in a program is not a raise: the cheque is the figure recorded with the place, which is the program's standard terms where we hold them, and a blank is one we don't.
| Member | Program | Announced | Cheque | Sources |
|---|---|---|---|---|
| Curlew Bio | Brisbane Pod | undated | - | Business News Australia, moleculetomedicine.com |
Portfolio
Companies Molecule to Medicine has backed in a published round, and companies whose existing shares it bought off another holder.
| Company | What it does | First invested | Rounds | Led |
|---|---|---|---|---|
| Curlew Bio | Accelerator | 1 | 1 |
Funds
Fund closes reported for Molecule to Medicine, as distinct from the investments it has made.
Portfolio companies acquired
Companies Molecule to Medicine has backed that another company then bought. An exit for the holding, not a deal Molecule to Medicine did.
People
Coverage
Stories naming Molecule to Medicine. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Unnamed stage
$1m
UQ biotech innovation partnership forges a second startup
UniQuest and Molecule to Medicine have formed Curlew Bio to develop anti-inflammatory drugs, backed by $1 million from UniQuest's Extension Fund; the article also recalls Novartis's 2015 purchase of Spinifex Pharmaceuticals.